alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 31.4





CERTIFICATIONS





I, John G. Cooper, certify that:





1.     I have reviewed this Amendment No. 1 on Form 10-K/A for the fiscal year ended December 31, 2011 of Discovery Laboratories, Inc.; and





2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.





Date:  April 27, 2012
/s/ John G. CooperJohn G. CooperPresident and Chief Financial Officer
Exhibit
15.2




To the
Board of Directors and Partners of


Icahn
Enterprises L.P.





We are
aware of the inclusion in Icahn Enterprises L.P.’s Form 10-Q for the quarter
ended March 31, 2010 and the incorporation by reference in the Registration
Statement (Form S-3 No. 333-143930) of Icahn Enterprises L.P. of our report
dated April 28, 2010 relating to the unaudited consolidated interim financial
statements of Federal-Mogul Corporation that are included in Federal-Mogul
Corporation’s Form 10-Q for the quarter ended March 31, 2010.





/s/ Ernst
and Young LLP




Detroit,
Michigan


May 6,
2010
**Exhibit 32**

 

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED**

**PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

Thecertifications set forth below are hereby submitted to the Securities andExchange Commission pursuant to, and solely for the purpose of complying with,Section 1350 of Chapter 63 of Title 18 of the United States Code in connectionwith the filing on the date hereof with the Securities and Exchange Commissionof the Quarterly Report on Form 10-Q of the Company for the quarterended September 30, 2010.

 

Each of the undersignedhereby certifies in their capacity as an officer of Citizens BancsharesCorporation and subsidiary (the “Company”) that, to their knowledge on the dateof this certification, the Quarterly Report of the Company on Form 10-Q for theperiod ended September 30, 2010 fully complies with the requirements of Section13(a) or 15(d) of the Securities Exchange Act of 1934 and that the informationcontained in such report fairly presents, in all material respects, thefinancial condition of the Company at the end of such period and the results ofoperations of the Company for such period.

 

 
| Date:   November 15, 2010 | By:                                    | /s/ James E. Young |
|-------------------------------------|----------------------------------------|--------------------|
|                                | James E. Young                         |
|                                | President and Chief  Executive Officer |
|                                |                                   |
|                                |                                   |
| Date:   November 15, 2010 | By:                                    | /s/ Cynthia N. Day |
|                                | Cynthia N. Day                         |
|                                | Senior Executive Vice  President and   |
|                                | Chief Operating Officer                |
|                                |                                   |
|                                |                                   |
| Date:   November 15, 2010 | By:                                    | /s/ Samuel J. Cox  |
|                                | Samuel J. Cox                          |
|                                | Executive Vice President  and          |
|                                | Chief Financial Officer                |

 

1

----
N 

March 15, 2012 

Mr. James M. Crotty 

Office of Rulemaking -Aircraft and Airports Division 

Federal Aviation Administration - National Headquarters 

800 Independence Avenue, SW 

Room 810, FOB10A 

Washington, DC 20591 

Re: Request for Ninety Day 190\ Temporarv Relief to the Compliance Date for Upgraded 

Cockpit Voice Recorder Required by 14 CFR Part 121.359(i) in order to Allow for Processing 

Seaborne Airlines' Exemption Petition. 

In part, the provisions of 14 CFR Part 121359(i), Cockpit Voice Recorders, requires Seaborne 

Airlines to have installed upgraded Cockpit Voice Recorders in their aircraft after April 7, 2012. 

On January 26, 2012, Seaborne Airlines submitted a request (FR Docket ID# FAA-2012-0098) 

for a temporary extension to the compliance date for three (3) of its aircraft to certain provisions 

of 14 CFR 121.359(i). 

With the compliance date of April7, 2012, only days away, there is insufficient time for 

Seaborne Airlines to acquire the equipment and make the required modifications without 

removing the aircraft from service. Since it appears that the FAA may need additional time to 

evaluate the airline's exemption request, in the absence of exemption relief, Seaborne Airlines 

will be faced with cancelling passenger flights and interrupting a portion of the region's essential 

air service. 

As a result, Seaborne Airlines is requesting that the FAA immediately grant an extension of 

ninety days (90) to the compliance date for the upgraded cockpit voice recorder for the three (3) 

aircraft listed in the exemption petition. This will provide the time needed for the FAA to 

complete the evaluation of the initial exemption petition. 

We believe that granting this exemption is in the public interest since Seaborne Airlines will be 

able to continue to provide essential passenger service while it either resolves the applicability 

issue or makes the required modification to the aircraft. 

s;ooorn' ~ 

~" Chief Operating Officer 

Seaborne Airlines 

(340) 773-5991 extension 60 

dziemer@seaborneairlines.com
Michigan Supreme Court

Lansing, Michigan

Stephen J. Markman

, Chief Justice

Brian K. Zahra

Bridget M. McCormack

David F. Viviano

Richard H. Bernstein

Joan L. Larsen,

Justices

I, Larry S. Royster , Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

May 2, 2017

a0424 

# Order

Clerk May 2, 2017

154166

- 7

ANTHONY V. MARROCCO,

Plaintiff

- Appellant,

v SC: 154166

- 7

COA: 326575; 327614

Macomb CC: 2013

- 002615

- CZ

OAKLAND MACOMB INTERCEPTOR DRAIN

DRAINAGE DISTRICT, JIM NASH, and

MICHAEL GREGG,

Defendants

- Appellees.

_________________________________________/

On order of the Court, the application for leave to appeal the June 16, 2016

judgment of the Court of Appeals is considered, and it is DENIED, because we are not

persuaded that the questions presented should be reviewed by this Court.

V IVIANO , J., did not participate due to a familial relationship with counsel of

record. MCR 2.003(C)(1)(g)(ii)

.
§ 20.21 Uniform access to records. Any record of the Food and Drug Administration that is disclosed in an authorized manner to any member of the public is available for disclosure to all members of the public, except that: ( a ) Data and information subject to the exemptions established in § 20.61 for trade secrets and confidential commercial or financial information, and in § 20.63 for personal privacy, shall be disclosed only to the persons for the protection of whom these exemptions exist.
( b ) The limited disclosure of records permitted in § 7.87(c) of this chapter for section 305 hearing records, in § 20.80(b) regarding certain limitations on exemptions, in § 20.103(b) for certain correspondence, and in § 20.104(b) for certain summaries of oral discussions, shall be subject to the special rules stated therein.
( c ) Disclosure of a record about an individual, as defined in § 21.3(a) of this chapter, that is retrieved by the individual's name or other personal identifier and is contained in a Privacy Act Record System, as defined in § 21.3(c) of this chapter, shall be subject to the special requirements of part 21 of this chapter. Disclosure of such a record to an individual who is the subject of the record does not invoke the rule established in this section that such records shall be made available for disclosure to all members of the public.
[42 FR 15616, Mar. 22, 1977, as amended at 54 FR 9037, Mar. 3, 1989]
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                             587
<SECURITIES>                                         0
<RECEIVABLES>                                    7,275
<ALLOWANCES>                                     1,569
<INVENTORY>                                      2,472
<CURRENT-ASSETS>                                10,914
<PP&E>                                           9,507
<DEPRECIATION>                                  (2,869)
<TOTAL-ASSETS>                                  17,742
<CURRENT-LIABILITIES>                           11,306
<BONDS>                                            374
<PREFERRED-MANDATORY>                           36,298
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                    17,742
<SALES>                                         23,202
<TOTAL-REVENUES>                                23,202
<CGS>                                           36,364
<TOTAL-COSTS>                                   24,213
<OTHER-EXPENSES>                                  (946)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               1,121
<INCOME-PRETAX>                                (37,550)
<INCOME-TAX>                                    (1,125)
<INCOME-CONTINUING>                            (37,550)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (36,425)
<EPS-PRIMARY>                                   (51.59)
<EPS-DILUTED>                                   (51.59)
        

</TABLE>
### Floods of 1952 in the basins of the upper Mississippi River and Red River of the North

By: J. V. B. Wells

                            https://doi.org/10.3133/wsp1260C

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plate:  **Plate 1**                            (pdf)
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
Editorial Note on Part 201
Editorial Note: Nomenclature changes to part 201 appear at 69 FR 13717, Mar. 24, 2004.

§ 201.161 Medical gases. Cross Reference
Link to an amendment published at 89 FR 51768 , June 18, 2024.
( a ) Oxygen, nitrogen, carbon dioxide, helium, and nitrous oxide gases intended for drug use, and medically appropriate combinations of any of these gases intended for drug use, are exempted from the requirements of § 201.100(b)(2) and (3), and (c)(1), provided that, where applicable, the requirements of §§ 201.328 and 211.94(e)(2) of this chapter are met and the labeling bears, in addition to any other information required by the Federal Food, Drug, and Cosmetic Act, the following: ( 1 ) ( i ) In the case of oxygen, a warning statement providing that uninterrupted use of high concentrations of oxygen over a long duration, without monitoring its effect on oxygen content of arterial blood, may be harmful; that oxygen should not be used on patients who have stopped breathing unless used in conjunction with resuscitative equipment; and, in the case of oxygen that may be provided without a prescription for use in the event of depressurization or other environmental oxygen deficiency, or for oxygen deficiency or for use in emergency resuscitation when administered by properly trained personnel, a warning statement providing that oxygen may be used for emergency use only when administered by properly trained personnel for oxygen deficiency and resuscitation, and that for all other medical applications a prescription is required.
( ii ) In the case of nitrogen, carbon dioxide, helium, nitrous oxide, and medically appropriate combinations of any of the gases listed in paragraph (a) of this section, a warning statement providing that the administration of the gas or gas combination (as applicable) may be hazardous or contraindicated; and that the gas or gas combination (as applicable) should be used only by or under the supervision of a licensed practitioner who is experienced in the use and administration of the gas or gas combination (as applicable) and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken.
( 2 ) Any needed directions concerning the conditions for storage and warnings against the inherent dangers in the handling of the specific compressed gas.
( b ) [Reserved]
[81 FR 81696, Nov. 18, 2016]
§ 500.55 Exemption from certain drug-labeling requirements. ( a ) Section 201.105(c) of this chapter provides that in the case of certain drugs for which directions, hazards, warnings, and use information are commonly known to practitioners licensed by law, such information may be omitted from the dispensing package. Under this proviso, the Commissioner of Food and Drugs will offer an opinion, upon written request, stating reasonable grounds therefore on a proposal to omit such information from the dispensing package.
( b ) The Commissioner of Food and Drugs has considered submitted material covering a number of drug products and has offered the opinion that the following drugs when intended for those veterinary uses for which they are now generally employed by the veterinary medical profession, should be exempt from the requirements of § 201.105(c) of this chapter, provided that they meet the conditions prescribed in this paragraph. Preparations that are not in dosage unit form (for example, solutions) will be regarded as meeting the conditions with respect to the maximum quantity of drug per dosage unit if they are prepared in a manner that enables accurate and ready administration of a quantity of drug not in excess of the stated maximum per dosage unit:
*Atropine sulfate.* As an injectable for cattle, goats, horses, pigs, and sheep, not in excess of 15 milligrams per dosage unit; as an injectable for cats and dogs, not in excess of 0.6 milligram per dosage unit. *Barbital sodium.* For oral use in cats and dogs, not in excess of 300 milligrams per dosage unit. *Epinephrine injection. 1:1,000.* For cats, dogs, cattle, goats, horses, pigs, and sheep (except as provided in § 500.65). *Morphine sulfate.* As an injectable for dogs, not in excess of 15 milligrams per dosage unit. *Pentobarbital sodium.* For oral use in cats and dogs, not in excess of 100 milligrams per dosage unit. *Phenobarbital sodium.* For oral use in cats and dogs, not in excess of 100 milligrams per dosage unit. *Procaine hydrochloride injection.* Containing not in excess of 2 percent procaine hydrochloride, with or without epinephrine up to a concentration of 1:50,000. For use in cats, dogs, cattle, goats, horses, pigs, and sheep. *Thyroid.* For oral use in dogs, not in excess of 60 milligrams per dosage unit.
#### Slotnik v. Winston et al.

*James Terpolilli,*for plaintiff.

*Morris B. Levitt,*for defendants.

September 26, 1951.

Smith, P. J.,

— This matter comes before the court on defendants’ motion and rule to strike off a judgment against James C. Winston in the sum of $638.44.

The judgment was entered by plaintiff against Winston without order or decree of this court. The original action is in equity to set aside a sale by Winston and Friedant of a grocery store because of alleged violation of the provisions of the Bulk Sales Act. In the joint answer defendant Winston admitted an indebtedness to plaintiff in the sum of $638.44, but denied that complainant was entitled to any relief prayed for since the sale had taken place more than 90 days before the bill was filed, contrary to the provisions of section 3 of the Bulk Sales Act of May 23,1919, P. L. 262.

After the answer was filed complainant on August 20, 1951, by an order or prascipe of his attorney upon the prothonotary caused a judgment to be entered against Winston for the amount admitted to be due in the answer.

The attorney for plaintiff exceeded his authority and the prothonotary had no power to enter this judgment in a proceeding arising in equity as written. *143Rule of Civil Procedure 1037, providing for the entry of a judgment in civil cases, does not cover proceedings in equity. In equity a judgment may not be entered without first having had an order or decree of the chancellor. In action in equity, facts admitted require no proof on the trial in equity but there is no provision for the taking of a judgment by the attorney for plaintiff without first having had the order or decree of the court.

*Order*

And now, to wit, September 26, 1951, the motion and rule of defendant to strike off the judgment against James C. Winston is granted and the prothonotary is directed to strike off the judgment against James C. Winston.
<PAGE>   1
                                                                    Exhibit 10.6


                     AMENDMENT NO. 2 TO LICENSE, DEVELOPMENT
                              AND SUPPLY AGREEMENT

This Amendment No. 2 to License, Development and Supply Agreement, dated as of
June 5th, 1998, is entered into by and between ABBOTT LABORATORIES , an Illinois
corporation ("Abbott") and CORIXA CORPORATION, a Delaware corporation
("Corixa").

                                    RECITALS

            WHEREAS, Corixa and Abbott are parties to that certain License,
Development and Supply Agreement, dated July 24,1997 and amended by Letter
Agreement on May 22, 1998, (the "License Agreement").

            WHEREAS, the parties desire to amend the License Agreement, to
modify certain provisions thereof regarding Milestone Payments.

            NOW THEREFORE, the parties hereto agree as follows:

                                    AMENDMENT

1.          Except as otherwise defined herein, capitalized terms used in this
            Amendment shall have the meanings designated in the License
            Agreement.

2.          Section 3.2 (a) the License Agreement is hereby amended in its
            entirety to read as follows:

            3.2 (a)     Abbott shall pay Corixa [***] within thirty (30)
                        days following Abbott's initiation of clinical trials of
                        Licensed Product.

3.          Except as amended hereby, the License Agreement shall continue in
            full force and effect in accordance with its terms.

4.          This Amendment No. 2 shall be governed by and construed in
            accordance with the laws of the state of Washington, regardless of
            its or any other jurisdiction's choice of law provisions.

            IN WITNESS WHEREOF, the parties hereto have executed this Agreement
as of the date first above written.


ABBOTT LABORATORIES                            CORIXA CORPORATION


By:  /s/ James J. Koziarz                      /s/ Mark McDade
Its: Corporate Vice President, Diagnostic      Mark McDade, Chief Operating
     Research and Development                  Officer
§ 524.900 Famphur. ( a ) *Specifications.* The drug is in liquid form containing 13.2 percent famphur.
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) *Special considerations.* Do not use on animals simultaneously or within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals.
( d ) *Related tolerances.* See § 556.273 of this chapter.
( e ) *Conditions of use* — ( 1 ) *Amount.* Apply 1 ounce per 200 pounds body weight, not to exceed a total dosage of 4 ounces, from the shoulder to the tail head as a single treatment. Apply as soon as possible after heel fly activity ceases.
( 2 ) *Indications for use in beef and nonlactating dairy cattle.* For control of cattle grubs and to reduce cattle lice infestations.
( 3 ) *Limitations.* Do not slaughter within 35 days after treatment. Do not use on lactating dairy cows or dry dairy cows within 21 days of freshening, calves less than 3 months old, animals stressed from castration, overexcitement or dehorning, sick or convalescent animals. Animals may become dehydrated and under stress following shipment. Do not treat until they are in good condition. Brahman and Brahman crossbreeds are less tolerant of cholinesterase-inhibiting insecticides than other breeds. Do not treat Brahman bulls. Swine should be eliminated from area where runoff occurs.
[40 FR 13873, Mar. 27, 1975, as amended at 49 FR 34352, Aug. 30, 1984; 57 FR 7652, Mar. 4, 1992; 59 FR 28769, June 3, 1994; 62 FR 55161, Oct. 23, 1997; 62 FR 61626, Nov. 19, 1997; 69 FR 41427, July 9, 2004; 79 FR 10968, Feb. 27, 2014; 83 FR 48946, Sept. 28, 2018]
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

# FOR FURTHER INFORMATION CONTACT:

                        To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Ms. Cheryl Nelson, Project Officer, NIH, NHLBI, 6701 Rockledge Drive, MSC 7934, Bethesda, MD 20892-7934, or call non-toll-free number 301-435-0451 or E-mail your request, including your address to:                         *NelsonC@nhlbi.nih.gov.*

*Comments Due Date:*                         Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.                    

Suzanne Freeman, 

NHLBI Project Clearance Liaison,  National Institutes of Health.

Michael Lauer,

Director, DCVS,  National Institutes of Health.

[FR Doc. 2010-419 Filed 1-12-10; 8:45 am]

BILLING CODE 4140-01-P